WHWK
NASDAQWhitehawk Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$4.11-0.13 (-3.07%)
01:30 PM07:45 PM
News · 26 weeks54-29%
2025-12-212026-06-14
Mix4290d
- Insider23(55%)
- Other9(21%)
- SEC Filings9(21%)
- Offering1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Zhao Baiteng4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Director Reeve Emma4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Director Maroun Richard E4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Director Hirmand Mohammad4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Director Desai Neil4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Director Castelein Caley4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Director Aghazadeh Behzad4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- SECWhitehawk Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
- SECSEC Form EFFECT filed by Whitehawk Therapeutics Inc.EFFECT - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
- PRWhitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026MORRISTOWN, N.J., May 30, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of tar
- SECSEC Form S-3 filed by Whitehawk Therapeutics Inc.S-3 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
- PRWhitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare ConferenceMORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will present at the Jefferies 2026 Global Healthcare Conference in New York City, NY on Thursday, June 4 at 8:10 AM ET.A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.About Whitehawk TherapeuticsWhitehawk Therapeutics is a clinical-sta
- SECSEC Form 8-K filed by Whitehawk Therapeutics Inc.8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
- PRWhitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-PayloadAgreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload VariationsHangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC PlatformPhase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCOMORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into a new op
- PRWhitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation SummitMORRISTOWN, N.J., May 20, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026, at 11:00 AM ET.A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.About Whitehawk Thera
- INSIDERChief Medical Officer Dugan Margaret was granted 19,132 shares (SEC Form 4)4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDEROfficer Ball Bryan was granted 51,020 shares, increasing direct ownership by 13% to 448,126 units (SEC Form 4)4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Giacobello Scott M. was granted 38,265 shares, increasing direct ownership by 13% to 333,489 units (SEC Form 4)4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Lennon David James was granted 51,021 shares, increasing direct ownership by 10% to 569,643 units (SEC Form 4)4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERDirector Castelein Caley was granted 255,102 shares, increasing direct ownership by 1,295% to 274,796 units (SEC Form 4)4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- PRWhitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology ForumMORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual Targeted Oncology Forum on Tuesday, May 19, 2026, at 3 PM ET.A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.About Whitehawk Therapeutics Whitehawk Therapeutics is
- INSIDERSEC Form 4 filed by Director Avoro Capital Advisors Llc4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- SECWhitehawk Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
- PRWhitehawk Therapeutics Announces $87.5M Private Placement Equity FinancingMORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $87.5 million, before deducting placement agent fees and other private placement expenses.The PIPE financing includes partici
- SECSEC Form 10-Q filed by Whitehawk Therapeutics Inc.10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
WHWK FAQ
5 questionsWhere does WHWK stock trade?
Whitehawk Therapeutics Inc. (WHWK) is listed on NASDAQ.What sector and industry is WHWK in?
Whitehawk Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about WHWK?
Whitehawk Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Oppenheimer: Outperform with a $600.00 price target on 2026-02-05. Recent price targets cluster around $600.00.What companies are similar to WHWK?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare WHWK side-by-side with any of them on Quantisnow.How can I track WHWK on Quantisnow?
Quantisnow aggregates Whitehawk Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WHWK to receive live email and push alerts on every new disclosure.